CureVac (NASDAQ:CVAC - Get Free Report) shares saw unusually-strong trading volume on Tuesday . Approximately 1,377,593 shares changed hands during mid-day trading, a decline of 18% from the previous session's volume of 1,689,576 shares.The stock last traded at $4.93 and had previously closed at $4.44.
Wall Street Analyst Weigh In
Separately, JMP Securities restated a "market outperform" rating and set a $16.00 target price on shares of CureVac in a research note on Monday, September 16th.
Get Our Latest Report on CVAC
CureVac Price Performance
The business's fifty day moving average price is $3.00 and its 200 day moving average price is $3.13. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The stock has a market cap of $1.05 billion, a P/E ratio of 8.51, a PEG ratio of 0.24 and a beta of 2.50.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Private Advisor Group LLC acquired a new stake in shares of CureVac in the third quarter valued at about $30,000. International Assets Investment Management LLC bought a new stake in shares of CureVac during the third quarter worth about $35,000. Integrated Wealth Concepts LLC bought a new stake in CureVac during the third quarter worth $35,000. Bank of New York Mellon Corp bought a new position in CureVac in the 2nd quarter valued at $54,000. Finally, Barclays PLC purchased a new stake in shares of CureVac during the 3rd quarter worth approximately $67,000. 17.26% of the stock is currently owned by institutional investors.
CureVac Company Profile
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Recommended Stories
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
